July 12, 2021 5:21pm

Quarterly reporting LPS (loss-per-share) is coming

Pre-open indications: 4 HITs and 1 MISS

My comments try to distinguish the temporary from real pricing digression or progress.

It takes courage to not be discouraged by sector volatility!

 

The Dow closed UP +130.76 points (+0.37%); the S&P closed UP +15.07 points (+0.34%) while the Nasdaq closed UP +31.32 points (+0.21)

 

Henry’omics:

Indexes have experienced yet another record high while the cell and gene therapy sector got churned.

 

RegMed Investors’ (RMi) pre-open: “Watching the rain come down” … https://www.regmedinvestors.com/articles/11993  

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Monday opened negative at 5/27, 2 flats and 1 acquired, stayed negative at the mid-day to 27/6, 2 flats and 1 acquired, closing negative 11/19, 4 flats and 1 acquired;

 

The Biostage (BSTG) Chronicles: The “pump” is STILL promoting on Monday as 2,628 shares traded with a NEGATIVE -$0.00 upside after Friday as 1060 shares traded with the share price closing FLAT after Thursday with 210 shares traded and Wednesday with 15,903 shares traded to “push/promote” the exercise of warrants to add more unregistered shares to the “outstanding” … WHO and WHOM are trading – as if we didn’t know?

 

Pre-open Indications: 4 HITs < Maintaining SELL: Biostage (BSTG -$0.00); SELL: CRISPR Therapeutics (CRSP -$3.58), Fate Therapeutics (FATE -$4.53), Global Blood Therapeutics (GBT -$0.41) and 1 MISS < bluebird bio (BLUE) -$0.78)>

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results: https://www.regmedinvestors.com/articles/11628

 

There are clear winners and losers

Jumping with share pricing momentum:

  • Vericel (VCEL), AxoGen (AXGN), BioLife Solutions (BLFS), Alnylam Pharmaceuticals (ALNY), Homology Medicine (FIXX) to name 5 of the 11 inclining of the 35

Hammered in today’s market:

  • Fate Therapeutics (FATE), Intellia Therapeutics (NTLA), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Ionis Pharmaceuticals (IONS) to name 5 of the 19 declining of the 35 covered

 

Key Metrics:

  • Sector volume was LOW with 2 of the 11-upside having higher than the 3-month average volume with NADA volume of 0 of 19-downside having higher than the 3-month average volume;
  • Monday’s percentage (%) of the 11-upside were +0.04% (RARE) to +11.28% (BLCM) while the 19-downside ranges from -0.64% (MESO) to -5.15% (EDIT);

 

Monday’s (11 of 11) incliners:

  • AxoGen (AXGN +$1.02);
  • Vericel (VCEL -$0.87);
  • BioLife Solutions (BLFS +$0.670;
  • Alnylam Pharmaceuticals (ALNY +$0.29);
  • Homology Medicine (FIXX +$0.14);
  • Bellicum Pharmaceuticals (BLCM +$0.08);
  • Brainstorm Cell Therapeutics (BCLI +$
  • Chinook Therapeutics (KDNY +$0.07);
  • Ultragenyx (RARE +$0.04);
  • Caladrius Biosciences (CLBS +$0.02);
  • MiMedx (MDXG +$0.01);

Monday’s (10 of 19) decliners:

  • Intellia Therapeutics (NTLA -$4.97);
  • Fate Therapeutics (FATE -$4.53);
  • CRISPR Therapeutics (CRSP -$3.58);
  • Editas Medicine (EDIT -$2.50);
  • Ionis Pharmaceuticals (IONS -$1.58);
  • Sage Therapeutics (SAGE -$1.00);
  • bluebird bio (BLUE -$0.78);
  • Regenxbio (RGNX -$0.77);
  • uniQure NV (QURE -$0.60);
  • Sangamo therapeutics (SGMO -$0.45);

Closing - 4 – Verastem (VSTM), Biostage (BSTG), ReNeuron (RENE.L), Athersys (ATHX) and 1 - Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB closed down -0.37% and XBI closed down -1.47%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was down -0.01 points or -0.06% at 16.17

Upside volume:

  • Monday: 2 out of the 11-upside had higher than the 3-month average volume;

Downside volume:

  • Monday: 0 out of the19-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: price versus percentage …

  • Monday’s percentage (%) of the 11-upside were +0.04% (RARE) to +11.28% (BLCM) while the 19-downside ranges from -0.64% (MESO) to -5.15% (EDIT);

 

July, first month of Q3/21:

Monday closed negative with 11 advancers, 19 decliners, 4 flat and 1 acquired

 

The BOTTOM LINE:  Back on the roller-coaster … 

I expect smaller and choppier gains, brace for more volatility.

Next few months – unless, news of clinical results or an M&A after a choppy and marginal performance in the first half.

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

July starts on a positive note, and be careful of a long, hot, volatile summer.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.